Showing 1 - 6 of 6 Tejal Patel

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Status: Open Not Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting el ... Read more >

Live Chat Available